Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis
Surgical Practice · 2022-08 · 26 (3) · 155-164
DOI: 10.1111/1744-1633.12578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Practice, online erschienen am 27.05.2022. Verfasst von Carlo Alberto Pacilio und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
Most patients with pancreatic ductal adenocarcinoma receive chemo‐radiotherapy as first approach, some of them with the future hope to undergo surgery. Methodology The aim of the study was to estimate the probabilities to receive surgery, to experience tumour progression or post‐operative recurrence. We performed a competing‐risk approach to estimate competing events of disease progression and surgery, as well as post‐operative recurrence and death without recurrence.
Results
Of 96 enrolled patients, 49 received chemotherapy because they were judged borderline resectable, 21 were locally advanced and 7 had liver‐only limited metastatic disease. Competing‐risk analyses showed that resectability status at diagnosis not only determines future probabilities of surgery, but also tumour progression and post‐operative recurrence ( p < .05 in all cases). CA19‐9 decrease ≥50% predicted surgery ( p = .032), whereas CA19‐9 ≥ 300 U/mL predicted post‐operative recurrence ( p = .001). Younger age also predicted surgery ( p = .001) and margin status predicted recurrence ( p = .047). The combination of the competing events suggested that the best outcomes since diagnosis depended not only on resectability and final surgical margin, but also on the combination of relative decrease of CA19‐9 and its absolute value after therapy.
Conclusions
The combination of CA19‐9 decrease, added to resectability criteria, can be used to optimise the selection of surgical candidates.
Zitieren
APA
Pacilio, C. A., Grassi, E., Gardini, A., Fappiano, F., Passardi, A., Frassineti, G. L., Tamberi, S., & Ercolani, G. (2022). Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis. Surgical Practice, 26(3), 155-164. https://doi.org/10.1111/1744-1633.12578
Vancouver
Pacilio CA, Grassi E, Gardini A, Fappiano F, Passardi A, Frassineti GL, et al. Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis. Surgical Practice. 2022;26(3):155-164. doi:10.1111/1744-1633.12578
BibTeX
@article{Pacilio2022,
author = {Pacilio, Carlo Alberto and Grassi, Elisa and Gardini, Andrea and Fappiano, Francesca and Passardi, Alessandro and Frassineti, Giovanni Luca and Tamberi, Stefano and Ercolani, Giorgio},
title = {Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis},
journal = {Surgical Practice},
year = {2022},
volume = {26},
number = {3},
pages = {155--164},
doi = {10.1111/1744-1633.12578}
}
EUVIMED